---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073437"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:37:57.777684+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026

## Summary
- Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.
- Cash $602.1M as of Dec 31, 2025, up from $302.1M; runway into 3Q 2028.
- WVE-007 obesity: INLIGHT Phase 1 showed fat loss similar to GLP-1 at 240mg; Phase 2a multidose planned 1H 2026.
- WVE-006 for AATD: regulatory engagement for accelerated approval; feedback expected mid-2026; 400mg multidose data in Q1 2026.
- GSK collaboration selected fourth program in Jan 2026; eligible for up to $2.8B milestones.

## SEC filing metadata
- accession: 0001193125-26-073437
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/0001193125-26-073437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/d103046d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073437
- JSON: https://secwatch.observer/filing/0001193125-26-073437.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.